First Trust Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-41,230
| Closed | -$462K | – | 2527 |
|
|
2017
Q3 | $462K | Sell |
41,230
-11
| -0% | -$121 | ﹤0.01% | 2113 |
|
|
2017
Q2 | $454K | Sell |
41,241
-1,125
| -3% | -$11.3K | ﹤0.01% | 2105 |
|
|
2017
Q1 | $415K | Sell |
42,366
-14,878
| -26% | -$149K | ﹤0.01% | 2137 |
|
|
2016
Q4 | $618K | Buy |
57,244
+29,728
| +108% | +$297K | ﹤0.01% | 2026 |
|
|
2016
Q3 | $282K | Buy |
27,516
+1,757
| +7% | +$19.1K | ﹤0.01% | 2157 |
|
|
2016
Q2 | $336K | Sell |
25,759
-1,384
| -5% | -$18.1K | ﹤0.01% | 2060 |
|
|
2016
Q1 | $299K | Sell |
27,143
-1,089
| -4% | -$9.68K | ﹤0.01% | 2066 |
|
|
2015
Q4 | $260K | Sell |
28,232
-72
| -0.3% | -$603 | ﹤0.01% | 2096 |
|
|
2015
Q3 | $196K | Buy |
28,304
+4,895
| +21% | +$41.9K | ﹤0.01% | 2164 |
|
|
2015
Q2 | $230K | Sell |
23,409
-543
| -2% | -$4.95K | ﹤0.01% | 2137 |
|
|
2015
Q1 | $212K | Sell |
23,952
-67
| -0.3% | -$534 | ﹤0.01% | 2143 |
|
|
2014
Q4 | $210K | Sell |
24,019
-2,357
| -9% | -$19.1K | ﹤0.01% | 2162 |
|
|
2014
Q3 | $182K | Buy |
+26,376
| New | +$158K | ﹤0.01% | 2152 |
|
|
2013
Q3 | – | Sell |
-63,375
| Closed | -$314K | – | 2360 |
|
|
2013
Q2 | $314K | Buy |
+63,375
| New | +$302K | ﹤0.01% | 2012 |
|
First Trust Advisors's SCLN Position: Q4 2017 in Review
First Trust Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 41,230 shares — an estimated $462K sold.
First Trust Advisors first reported a position in SCLN in Q2 2013 and held it in 14 quarters. The position peaked at $618K in Q4 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- First Trust Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- First Trust Advisors sold 41,230 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $462K.
- First Trust Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 14 quarters.
- First Trust Advisors's Sciclone Pharmaceuticals Inc position peaked at $618K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on First Trust Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.